NCT00783549

A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.

A Study in Healthy Volunteers of Single Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Compound Alone and When Co-administered With Sitagliptin

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 76 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study is the first study in humans to assess the safety and tolerability of various doses of GSK1292263 alone, and taken with sitigliptan.

Conditions

• Dyslipidaemias

Interventions

Type	Name	Description
DRUG	an undetermined dose of GSK1292263	GSK investigational product or placebo
DRUG	ascending dose of GSK1292263	Ascending dose based on target exposures or placebo
DRUG	ascending dose of GSK1292263	An ascending dose based on target exposure
DRUG	ascending dose of GSK1292263	An ascending dose based on target exposures.
DRUG	ascending dose of GSK1292263	An ascending dose based on target exposure

Timeline

• Start date: 2008-09-04
• Primary completion: 2009-03-31
• Completion: 2009-03-31
• First posted: 2008-10-31
• Last updated: 2017-07-07

Locations

1 site across 1 country: United States